Baker McKenzie Baker McKenzie
How Can We Help?
  • Home
  • Expertise
  • Healthcare & Life Sciences

Healthcare & Life Sciences

Digital health
Insight | Thought Leadership

Hyper-Hybridity

This report explores trends and opportunities in digital health from the perspective of three key players in the ecosystem: healthcare and life sciences organizations, technology companies and investors.
Read More

Healthcare and life sciences are some of the largest and fastest-growing industries in the world, in addition to being the most regulated, with rapidly changing rules and regulations that often conflict from one country to another. Healthcare and life sciences companies face a number of challenges, including trying to understand how these laws impact their market and M&A strategies while contending with rising R&D costs, loss of patent protection of blockbuster drugs, pricing pressures, and competition from generics. Rapid convergence of the healthcare, life sciences and technology sectors requires even more legal expertise given the additional data privacy and intellectual property concerns.

Insight | Thought Leadership
The Year Ahead: Developments in Global Litigation and Arbitration in 2021
Key developments, risk areas and the factors likely to drive commercial disputes in each industry sector alongside specific local developments in 30 jurisdictions.
Insight | Thought Leadership
Hyper-Hybridity
This report explores trends and opportunities in digital health from the perspective of three key players in the ecosystem: healthcare organizations, technology companies and investors.
Insight | Recorded Webinar
Past Healthcare & Life Sciences Webinars
Learn more about the hot topics in the healthcare and life sciences industries.
Insight | Handbook
Unprecedented: Converging Crises
Industry insights and the potential implications for legal teams resulting from the COVID-19 pandemic.
Insight | Legal Alert
FDA's new guidance on emergency use authorizations for COVID-19 vaccines
On 22 October 2020, the FDA approved the anti-viral drug Veklury (remdesivir) for hospitalized COVID-19 patients, making it the first drug to receive approval for the treatment of COVID-19.
Insight | Thought Leadership
The Health Pod
The Health Pod, Baker McKenzie's industry podcast series, highlights sector-specific issues and trends that affect healthcare and life sciences companies.
Insight | Thought Leadership
Supply Chains Reimagined
With companies stabilizing supply chain operations and managing demand-side shocks, there is an opportunity to seek renewal through new, longer-term digital strategies.
Insight | Legal Alert
Life Sciences Collaborations: Key Considerations in the COVID-19 Era
We present some key considerations that companies in the sector need to bear in mind to cope with the growing complexities of licensing and collaboration agreements.
Insight
COVID-19: EU Leaders Reach Agreement on EUR 750 Billion (US 858 Billion) Recovery Plan
European leaders have agreed to create a recovery fund to support EU economies affected by COVID-19.
Insight | Legal Alert
Germany: COVID-19 Corporate Legal Guideline
Due to the situation caused by the spread of COVID-19, we have published a "Coronavirus - Legal Guide for Germany".
Insight | Handbook
Law on COVID19 in Poland - Handbook
A brief description of the changes most important for current and future economic landscape in Poland.
View All Insight
News | Deal Announcement
Baker McKenzie has successfully acted for HMS on its acquisition of Lorica Health
Baker McKenzie has successfully acted for HMS on its acquisition of Lorica Health, one of the largest payment accuracy solutions providers in Australia.
News | Deal Announcement
Baker McKenzie advises CureVac on vaccine alliance with Bayer
Baker McKenzie advised CureVac N.V. (Nasdaq: CVAC) on a collaboration and services agreement with Bayer AG.
News | Deal Announcement
Baker McKenzie advises Servier on the acquisition of the Agios Pharmaceuticals oncology business
The transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 billion plus royalties.
News | Deal Announcement
Baker McKenzie advises S Management AG on sale of majority share in SMEDICO
SMEDICO is an efficient distributor in the fragmented Swiss market with a strong market position in hospital and elderly care.
News | Deal Announcement
Baker McKenzie advises Allecra Therapeutics on exclusive licensing agreement with Shanghai Haini Pharmaceutical for Cefepime/Enmetazobactam for Greater China
Under the terms of the agreement, Allecra will receive payments and milestone fees in an amount of ...
News
Historic Year Sees Highest Global IPO Activity in a Decade with Surge in Domestic Listings and Continued Growth Predicted for 2021
IPO value growth due to a continuing trend toward mega deals driven by Chinese and US companies.
News
Competing Agendas of Digital Healthcare Players a Challenge, But Sector Opportunities Still Vast
In the wake of COVID-19, regulatory fragmentation, competing priorities and knowledge gaps are all currently creating impediments to the much needed development of digital healthcare in the Asia ...
News
Competing Agendas of Digital Healthcare Players a Challenge, Singapore cited as Global Hub for Healthcare-specific Investments
The ongoing COVID-19 global pandemic continues to starkly mark the challenges in digital healthcare ...
News | Deal Announcement
Baker McKenzie advises Novartis on achieving 100% renewable electricity in its European operations
Baker McKenzie has advised leading global medicines company Novartis on five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to ...
News | Deal Announcement
Baker McKenzie advises LIVEKINDLY on the acquisition of LikeMeat
Baker McKenzie advised The Livekindly Company, Inc. ("LIVEKINDLY Collective") on the acquisition of a 49% stake in LikeMeat from Recker Holding GmbH. LikeMeat is a Dusseldorf-based company ...
News | Deal Announcement
Baker McKenzie advises CatalYm on EUR 50 million Series B financing to advance immunoncology development
Baker McKenzie advised CatalYm, an innovative biotech company developing novel cancer ...
View All News
  • Ranked in the Top 10 Law Firms in the world for Life Sciences, Chambers Global
  • Ranked Band 1 for Life Sciences, Chambers Asia Pacific 2014-2018
  • Medical Law Firm of the Year, ALB Southeast Asia Awards 2017
  • Most Innovative Use of Technology for the Pharma MapApp, FT Most Innovative Lawyer Awards, 2015
  • No. 1 Healthcare M&A firm by deal volume for past three years, Thomson Reuters 2017
  • No. 1 Healthcare M&A firm by cross-border deal volume for past five years, Thomson Reuters 2017

 

How We Can Help

Explore Healthcare & Life Sciences

About Us

Learn about our Global Healthcare & Life Sciences Industry Group in 4 minutes
Stay tuned for upcoming webinars in 2021. See our past webinars. 

The Health Pod

Baker McKenzie's industry podcast series that highlights sector-specific issues and trends that affect healthcare & life sciences companies.

Life Sciences Collaborations: Key Considerations in the COVID-19 Era

A high-level guide that outlines a list of issues to consider in executing life sciences collaborations in the COVID-19 era

COVID-19: A Global Review of Healthcare and Life Sciences Industry Issues

Provides high-level answers to questions on market access, clinical trials, IP risks and telemedicine

Healthcare MapApp

Access real-time information on the laws and regulations affecting the healthcare and life sciences industries in more than 50 countries

Clinical Trials Handbook

Outlines the legal framework governing clinical trials of medicinal products in 34 jurisdictions

Promoting Medical Products Globally

Understand legal developments and regulations related to ethical business interactions between medical companies and healthcare professionals in 35 countries

Business success is being redefined as focus shifts to a greater purpose beyond profit. As COVID-19 puts a renewed spotlight on corporate citizenship, we can help you transform operations, manage risk and drive growth.

Key Contacts

We use cookies to improve your experience on our website. To find out more about the cookies we use and how to change your settings if you do not want cookies to be placed on your device, please read our Privacy and Cookies Statement.
Accept